Repeated Omicron Infections Overcome T Cell Immune Imprinting to Original SARS-CoV-2

J Med Virol. 2025 Feb;97(2):e70264. doi: 10.1002/jmv.70264.

Abstract

Multiple studies demonstrate the existence of attenuated neutralizing activity to the Omicron variants in the original SARS-CoV-2 strain vaccinated population undergoing breakthrough infection, which reflects a phenomenon of immune imprinting in humoral immunity. Herein, through designing spike protein peptide pools from four Omicron subvariants and the wild type (WT) counterpart, we intended to determine antiviral T cell immunoreactivity in Omicron-infected COVID-19 patients with or without previous vaccination. We have demonstrated that IFN-γ producing cells against the Omicron subvariants-derived peptide pools were significantly less than those against WT counterpart peptide pools in the Omicron BA.5/BA.7 infected patients receiving original inactivated SARS-CoV-2 vaccination whereas comparable in the unvaccinated group. Notably, reinfection with the Omicron subvariants restored viral-specific T cell immunity to the infected Omicron strains in vaccinated individuals. Therefore, similar to humoral immunity vaccination with the original SARS-CoV-2 strain-derived vaccines induces T cell immune imprinting when undergoing Omicron subvariants breakthrough infection. Since reinfection of Omicron subvariants can restore T cell immunoreactivity to the infected strains, it is necessary to design multivalent immunogens for vaccine development to overcome both B cell and T cell immune imprinting against SARS-CoV-2 and other highly mutant pathogens.

Keywords: COVID‐19 vaccines; Omicron reinfection; S protein‐specific IFN‐γ releasing level; SARS‐CoV‐2.

MeSH terms

  • Adult
  • Aged
  • Antibodies, Neutralizing / immunology
  • Antibodies, Viral / immunology
  • COVID-19 Vaccines* / immunology
  • COVID-19* / immunology
  • COVID-19* / prevention & control
  • COVID-19* / virology
  • Female
  • Humans
  • Immunity, Humoral
  • Interferon-gamma / immunology
  • Male
  • Middle Aged
  • Reinfection / immunology
  • SARS-CoV-2* / genetics
  • SARS-CoV-2* / immunology
  • Spike Glycoprotein, Coronavirus / genetics
  • Spike Glycoprotein, Coronavirus / immunology
  • T-Lymphocytes* / immunology
  • Vaccination

Substances

  • Spike Glycoprotein, Coronavirus
  • COVID-19 Vaccines
  • spike protein, SARS-CoV-2
  • Antibodies, Viral
  • Interferon-gamma
  • Antibodies, Neutralizing

Supplementary concepts

  • SARS-CoV-2 variants